Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma

World J Clin Cases. 2022 Dec 16;10(35):12804-12811. doi: 10.12998/wjcc.v10.i35.12804.

Abstract

Esophageal squamous cell carcinoma is one of the most common malignant tumors in the digestive system in China and the world. Most patients are diagnosed as locally advanced or advanced stage. Concurrent chemoradiotherapy is the standard treatment for locally advanced esophageal squamous cell carcinoma. This study intends to summarize the evidence-based medical evidence of the treatment principle of locally advanced esophageal squamous cell carcinoma, the selection of radiotherapy dose, the outline of radiotherapy target and the selection of chemotherapy scheme. As a result, the effect of radiotherapy and chemotherapy is equivalent to that of surgery for the radical treatment of esophageal squamous cell carcinoma. In the era of immunization, it is recommended to use involved field irradiation. Fluorouracil plus cisplatin regimen is the standard chemotherapy regimen. FOLFOX regimen and paclitaxel plus fluorouracil regimen are optional concurrent chemotherapy regimens. The toxic and side effects of different chemotherapy regimens are different, which can be selected according to the actual situation of patients.

Keywords: Chemoradiotherapy; Esophageal squamous cell carcinoma; Involving field irradiation; Radical radiotherapy and chemotherapy; Radical treatment.

Publication types

  • Review